|
2025
|
G/S
|
Pharmaceutical preparations for human use. |
|
|
G/S
|
Pharmaceutical preparations for the prevention and treatment of the central nervous system, namel... |
|
|
G/S
|
Pharmaceutical preparations for human use, namely biotics; food supplements. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of multiple sclerosis. |
|
|
G/S
|
Pharmaceutical preparations, namely antihypertonic preparations as well as urologic preparations. |
|
|
G/S
|
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal prep... |
|
2024
|
Invention
|
Crystalline forms of elacestrant dihydrochloride. The present invention relates to novel crystall... |
|
|
Invention
|
Cocrystals of vorasidenib. The present invention relates to vorasidenib solid-state forms, to a p... |
|
|
G/S
|
Préparations pharmaceutiques à usage humain pour la prévention et le traitement du système nerveu... |
|
|
G/S
|
Anti-infectives for human use; anti-inflammatories for human use; antibacterial pharmaceutical pr... |
|
|
Invention
|
Crystalline forms of tapinarof. The present invention relates to Tapinarof dimethylacetamide solv... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the trea... |
|
|
Invention
|
Drug delivery device |
|
|
G/S
|
Pharmaceutical preparations for human use, excluding eye treatment and contact lens solutions. |
|
|
G/S
|
Pharmaceutical preprations for human use, namely antipsychotic preparations. |
|
|
G/S
|
Pharmaceutical preparations for human use, namely antipsychotic preparations. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of Diabetes for human use. |
|
|
G/S
|
Pharmaceutical preparations for human use, excluding cardiovascular and hypertension disease trea... |
|
2023
|
Invention
|
Crystal form of a pde3/4 inhibitor. The present invention relates to a novel crystal of ensifentr... |
|
|
Invention
|
Stable composition comprising a high protein concentration. The present invention relates to aque... |
|
|
Invention
|
Particles comprising non-crystalline odevixibat. The invention relates to particles comprising od... |
|
2022
|
Invention
|
Inhaler device. The present invention relates to an inhaler device for use with an elongate strip... |
|
|
Invention
|
Process for the preparation of sucrose octasulfate octakistriethylammonium salt (tasos) powder an... |
|
|
Invention
|
Glass container with low aluminum content and gas overlay to prevent oxidation of sensitive thera... |
|
|
Invention
|
Crystalline form of acoramidis hydrochloride. The present invention relates to a crystalline form... |
|
|
Invention
|
Packaging |
|
|
Invention
|
Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-n-isopropylacetamide ... |
|
|
Invention
|
Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl )phenoxy)-n- isopropylacetamid... |
|
|
Invention
|
Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)p... |
|
|
Invention
|
Crystalline form of sotorasib.
The present invention relates to a crystalline form of sotorasib ... |
|
|
Invention
|
Crystalline form of sotorasib. The present invention relates to a crystalline form of sotorasib a... |
|
|
Invention
|
Inhaler |
|
|
Invention
|
Crystalline form of avacopan. The present invention relates to a crystalline form of avacopan, to... |
|
|
Invention
|
Control of n-terminal truncation by methionine supplementation. The present invention relates to ... |
|
|
Invention
|
Crystalline forms of mavacamten for the treatment of hcm. The present invention relates to anhydr... |
|
|
Invention
|
Crystalline form of risdiplam. The present invention relates to a crystalline form of risdiplam a... |
|
2021
|
Invention
|
Crystalline forms of pralsetinib. The present invention relates to crystalline forms of pralsetin... |
|
|
Invention
|
Crystalline form of selpercatinib. RETRET associated cancers, such as non-small cell lung cancer ... |
|
|
Invention
|
Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids.
The ... |
|
|
Invention
|
Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids. The p... |
|
|
Invention
|
Compositions comprising t-cells for topical administration to the lung. The present invention rel... |
|
|
Invention
|
Improved process for production of clavulanic acid. S. clavuligerusS. clavuligerus S. clavuligeru... |
|
|
Invention
|
High drug load tablet comprising voxelotor. A tablet comprising at least 60% w/w of voxelotor and... |
|
|
Invention
|
Compounds comprising voxelotor and 2,5-dihydroxybenzoic acid and crystal forms. The present inven... |
|
|
Invention
|
Parenteral pharmaceutical composition comprising azacitidine or decitabine in dmso.
The inventio... |
|
|
Invention
|
Parenteral pharmaceutical composition comprising azacitidine in dmso. A parenteral pharmaceutical... |
|
|
Invention
|
Multi-component compounds comprising zanubrutinib and a benzoic acid derivative. Sαα]pyrimidine-3... |
|
|
Invention
|
Counting devices.
A counting device for counting mechanical inputs comprising: a rotatably mount... |
|
|
Invention
|
Elagolix formulation. A pharmaceutical formulation is disclosed which includes at least: (1) elag... |
|
|
Invention
|
Crystalline eravacycline bis-hydrochloride.
The invention relates to crystalline eravacycline Ns... |
|
|
Invention
|
Polymorph of rucaparib mesylate. The present invention relates to an anhydrous crystalline form o... |
|
2020
|
Invention
|
Dose counting mechanism.
The present invention relates to dose counting mechanisms for medicamen... |
|
|
Invention
|
Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor.
The present ... |
|
2019
|
Invention
|
Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor. The present inv... |
|
|
Invention
|
Co-crystals comprising levothyroxine and a dicarboxylic acid. The present invention relates to co... |
|
|
Invention
|
An inhaler device.
The present invention relates to inhaler devices (701), and in particular to ... |
|
|
Invention
|
Process for preparing rapidly or very rapidly dissolving tablets comprising freely soluble api.
... |
|
2018
|
Invention
|
Co-crystal of an orally available janus kinase inhibitor.
The present invention relates to a co-... |
